Format

Send to

Choose Destination
Clin Chim Acta. 2019 Feb 3;492:20-22. doi: 10.1016/j.cca.2019.02.002. [Epub ahead of print]

Deamidated gliadin peptide in pediatric patients with moderately increased tissue transglutaminase; does it help?

Author information

1
Department of Laboratories, Seattle Children's Hospital, United States; Department of Laboratory Medicine, University of Washington, United States. Electronic address: Jane.dickerson@seattlechildrens.org.
2
Department of Gastroenterology, Seattle Children's Hospital, United States; Department of Pediatrics, University of Washington, United States.
3
Department of Laboratories, Seattle Children's Hospital, United States; Department of Anatomic Pathology, University of Washington, United States.

Abstract

BACKGROUND:

Deamidated gliadin peptide (DGP) is a relatively new serologic assay used in diagnosis and monitoring of celiac disease. DGP IgG is recommended by some in pediatric patients <2 y. Use in other pediatric populations is not well established. The utility of the DGP screen (IgG + IgA) in patients with moderate increase of tissue transglutaminase (TTG) IgA has not been studied.

METHODS:

Cases between January 2015 and October 2017 in which a patient had TTG IgA greater >19 and <100, DGP screen, and biopsy were collected. Indication for biopsy and diabetes diagnosis were recorded. Of 495 patients screened, 31 met criteria.

RESULTS:

The sensitivity and specificity of DGP screen were calculated, and were 87.4% and 56%, respectively; though lower in patients with diabetes.

CONCLUSIONS:

The study suggests in patients with moderately increased TTG-IgA, DGP screen lacks specificity and does not provide additional information about whether or not to biopsy.

KEYWORDS:

Celiac; Deamidated gliadin peptide (DGP); Laboratory; Pediatric; Tissue transglutaminase (TTG)

PMID:
30726722
DOI:
10.1016/j.cca.2019.02.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center